• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结直肠癌尿液生物标志物的鉴定:在资源有限的环境中开发结直肠癌筛查试验。

Identification of urinary biomarkers of colorectal cancer: Towards the development of a colorectal screening test in limited resource settings.

机构信息

Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada.

Department of Medicine, University of Alberta, Edmonton, AB, Canada.

出版信息

Cancer Biomark. 2023;36(1):17-30. doi: 10.3233/CBM-220034.

DOI:10.3233/CBM-220034
PMID:35871322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10627333/
Abstract

BACKGROUND

African colorectal cancer (CRC) rates are rising rapidly. A low-cost CRC screening approach is needed to identify CRC from non-CRC patients who should be sent for colonoscopy (a scarcity in Africa).

OBJECTIVE

To identify urinary metabolite biomarkers that, combined with easy-to-measure clinical variables, would identify patients that should be further screened for CRC by colonoscopy. Ideal metabolites would be water-soluble and easily translated into a sensitive, low-cost point-of-care (POC) test.

METHODS

Liquid-chromatography mass spectrometry (LC-MS/MS) was used to quantify 142 metabolites in spot urine samples from 514 Nigerian CRC patients and healthy controls. Metabolite concentration data and clinical characteristics were used to determine optimal sets of biomarkers for identifying CRC from non-CRC subjects.

RESULTS

Our statistical analysis identified N1, N12-diacetylspermine, hippurate, p-hydroxyhippurate, and glutamate as the best metabolites to discriminate CRC patients via POC screening. Logistic regression modeling using these metabolites plus clinical data achieved an area under the receiver-operator characteristic (AUCs) curves of 89.2% for the discovery set, and 89.7% for a separate validation set.

CONCLUSIONS

Effective urinary biomarkers for CRC screening do exist. These results could be transferred into a simple, POC urinary test for screening CRC patients in Africa.

摘要

背景

非洲结直肠癌(CRC)的发病率正在迅速上升。需要一种低成本的 CRC 筛查方法来识别应该接受结肠镜检查的 CRC 患者和非 CRC 患者(在非洲这种检查稀缺)。

目的

确定尿液代谢生物标志物,这些标志物与易于测量的临床变量相结合,可以识别需要进一步接受结肠镜检查筛查 CRC 的患者。理想的代谢物应该是水溶性的,并且易于转化为敏感、低成本的即时检测(POC)测试。

方法

使用液相色谱-质谱联用(LC-MS/MS)定量分析了 514 名尼日利亚 CRC 患者和健康对照者的尿液样本中的 142 种代谢物。代谢物浓度数据和临床特征用于确定用于通过 POC 筛查从非 CRC 受试者中识别 CRC 的最佳生物标志物组合。

结果

我们的统计分析确定 N1、N12-二乙酰精胺、马尿酸、对羟基马尿酸和谷氨酸是通过 POC 筛查区分 CRC 患者的最佳代谢物。使用这些代谢物加上临床数据进行逻辑回归建模,在发现组中的受试者工作特征(ROC)曲线下面积(AUCs)为 89.2%,在独立验证组中的 AUCs 为 89.7%。

结论

CRC 筛查的有效尿液生物标志物确实存在。这些结果可以转化为一种简单的 POC 尿液检测方法,用于筛查非洲的 CRC 患者。

相似文献

1
Identification of urinary biomarkers of colorectal cancer: Towards the development of a colorectal screening test in limited resource settings.结直肠癌尿液生物标志物的鉴定:在资源有限的环境中开发结直肠癌筛查试验。
Cancer Biomark. 2023;36(1):17-30. doi: 10.3233/CBM-220034.
2
Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection.结直肠癌患者血清中羟化、多不饱和超长链脂肪酸水平降低:对早期筛查和检测的意义。
BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.
3
Metabolomic Profiling Identified Serum Metabolite Biomarkers and Related Metabolic Pathways of Colorectal Cancer.代谢组学分析鉴定出结直肠癌的血清代谢物生物标志物及相关代谢途径。
Dis Markers. 2021 Dec 7;2021:6858809. doi: 10.1155/2021/6858809. eCollection 2021.
4
Specificity of metabolic colorectal cancer biomarkers in serum through effect size.通过效应大小分析血清中代谢性结直肠癌生物标志物的特异性。
Metabolomics. 2020 Aug 13;16(8):88. doi: 10.1007/s11306-020-01707-w.
5
Identification of Diagnostic Biomarkers for Colorectal Polyps Based on Noninvasive Urinary Metabolite Screening and Construction of a Nomogram.基于非侵入性尿液代谢物筛查的结直肠息肉诊断生物标志物鉴定及列线图构建
Cancer Med. 2025 Apr;14(7):e70762. doi: 10.1002/cam4.70762.
6
Urinary Metabolomics to Identify a Unique Biomarker Panel for Detecting Colorectal Cancer: A Multicenter Study.尿代谢组学鉴定用于结直肠癌检测的独特生物标志物组合:一项多中心研究。
Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1283-1291. doi: 10.1158/1055-9965.EPI-18-1291. Epub 2019 May 31.
7
LC-MS analysis of chiral amino acids in human urine reveals D-amino acids as potential biomarkers for colorectal cancer.LC-MS 分析人尿液中的手性氨基酸揭示 D-氨基酸可能作为结直肠癌的生物标志物。
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Sep 15;1245:124270. doi: 10.1016/j.jchromb.2024.124270. Epub 2024 Aug 5.
8
Altered Polyamine Profiles in Colorectal Cancer.结直肠癌中多胺谱的改变
Anticancer Res. 2018 Jun;38(6):3601-3607. doi: 10.21873/anticanres.12634.
9
Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.粪便蛋白作为非侵入性检测结直肠腺瘤高进展风险的生物标志物。
J Pathol. 2020 Mar;250(3):288-298. doi: 10.1002/path.5369. Epub 2020 Jan 13.
10
Global and targeted serum metabolic profiling of colorectal cancer progression.结直肠癌进展的整体及靶向血清代谢谱分析
Cancer. 2017 Oct 15;123(20):4066-4074. doi: 10.1002/cncr.30829. Epub 2017 Jun 22.

引用本文的文献

1
First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally.美国国立癌症研究所可负担癌症技术项目的首个十年:加速全球癌症转化技术研发
JCO Glob Oncol. 2025 Jul;11:e2500200. doi: 10.1200/GO-25-00200. Epub 2025 Jul 30.
2
Towards Automated Testing of Kynurenine for Point-of-Care Metabolomics.迈向用于即时护理代谢组学的犬尿氨酸自动化检测
Methods Protoc. 2025 Jun 1;8(3):56. doi: 10.3390/mps8030056.
3
Omics technologies as powerful approaches to unravel colorectal cancer complexity and improve its management.组学技术是揭示结直肠癌复杂性并改善其治疗的有力方法。
Mol Cells. 2025 May;48(5):100200. doi: 10.1016/j.mocell.2025.100200. Epub 2025 Feb 28.
4
From multi-omics to predictive biomarker: AI in tumor microenvironment.从多组学到预测性生物标志物:肿瘤微环境中的人工智能
Front Immunol. 2024 Dec 23;15:1514977. doi: 10.3389/fimmu.2024.1514977. eCollection 2024.

本文引用的文献

1
Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data.结直肠癌生存的全球模式与趋势:基于人群登记数据的系统综述
Cancer Biol Med. 2021 Sep 6;19(2):175-86. doi: 10.20892/j.issn.2095-3941.2020.0634.
2
Global colorectal cancer burden in 2020 and projections to 2040.2020年全球结直肠癌负担及到2040年的预测。
Transl Oncol. 2021 Oct;14(10):101174. doi: 10.1016/j.tranon.2021.101174. Epub 2021 Jul 6.
3
Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis.尿液中结直肠癌的综合挥发物组和代谢组特征:一项系统评价和荟萃分析
Cancers (Basel). 2021 May 21;13(11):2534. doi: 10.3390/cancers13112534.
4
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.结直肠癌筛查:美国预防服务工作组推荐声明。
JAMA. 2021 May 18;325(19):1965-1977. doi: 10.1001/jama.2021.6238.
5
Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health.人体和临床前研究宿主-肠道微生物群共代谢物马尿酸作为代谢健康的标志物和介质。
Gut. 2021 Nov;70(11):2105-2114. doi: 10.1136/gutjnl-2020-323314. Epub 2021 May 11.
6
Comprehensive Targeted Metabolomic Assay for Urine Analysis.用于尿液分析的综合靶向代谢组学检测
Anal Chem. 2020 Aug 4;92(15):10627-10634. doi: 10.1021/acs.analchem.0c01682. Epub 2020 Jul 21.
7
Fecal DNA Testing for Colorectal Cancer Screening.粪便 DNA 检测用于结直肠癌筛查。
Annu Rev Med. 2020 Jan 27;71:59-69. doi: 10.1146/annurev-med-103018-123125. Epub 2019 Aug 26.
8
Urinary Metabolomics to Identify a Unique Biomarker Panel for Detecting Colorectal Cancer: A Multicenter Study.尿代谢组学鉴定用于结直肠癌检测的独特生物标志物组合:一项多中心研究。
Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1283-1291. doi: 10.1158/1055-9965.EPI-18-1291. Epub 2019 May 31.
9
Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer.尿液-NMR 代谢组学用于筛查晚期结直肠腺瘤和早期结直肠癌。
Sci Rep. 2019 Mar 18;9(1):4786. doi: 10.1038/s41598-019-41216-y.
10
A Simple and Convenient Synthesis of Unlabeled and C-Labeled 3-(3-Hydroxyphenyl)-3-Hydroxypropionic Acid and Its Quantification in Human Urine Samples.未标记和C标记的3-(3-羟基苯基)-3-羟基丙酸的简便合成及其在人尿液样本中的定量分析
Metabolites. 2018 Nov 21;8(4):80. doi: 10.3390/metabo8040080.